Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Prenafeta, Antoni
- dc.contributor.author Cebollada Rica, Paula
- dc.contributor.author Sisteré-Oró, Marta
- dc.contributor.author Meyerhans, Andreas
- dc.contributor.author Ferrer, Laura
- dc.date.accessioned 2023-10-04T06:25:01Z
- dc.date.available 2023-10-04T06:25:01Z
- dc.date.issued 2023
- dc.description.abstract SARS-CoV-2 emerged in December 2019 and quickly spread worldwide, continuously striking with an unpredictable evolution. Despite the success in vaccine production and mass vaccination programs, the situation is not still completely controlled, and therefore accessible second-generation vaccines are required to mitigate the pandemic. We previously developed an adjuvanted vaccine candidate coded PHH-1V, based on a heterodimer fusion protein comprising the RBD domain of two SARS-CoV-2 variants. Here, we report data on the efficacy, safety, and immunogenicity of PHH-1V in cynomolgus macaques. PHH-1V prime-boost vaccination induces high levels of RBD-specific IgG binding and neutralizing antibodies against several SARS-CoV-2 variants, as well as a balanced Th1/Th2 cellular immune response. Remarkably, PHH-1V vaccination prevents SARS-CoV-2 replication in the lower respiratory tract and significantly reduces viral load in the upper respiratory tract after an experimental infection. These results highlight the potential use of the PHH-1V vaccine in humans, currently undergoing Phase III clinical trials.
- dc.format.mimetype application/pdf
- dc.identifier.citation Prenafeta A, Bech-Sàbat G, Moros A, Barreiro A, Fernández A, Cañete M, et al. Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates. iScience. 2023 Jun 28;26(7):107224. DOI: 10.1016/j.isci.2023.107224
- dc.identifier.doi http://dx.doi.org/10.1016/j.isci.2023.107224
- dc.identifier.issn 2589-0042
- dc.identifier.uri http://hdl.handle.net/10230/58035
- dc.language.iso eng
- dc.publisher Elsevier
- dc.relation.ispartof iScience. 2023 Jun 28;26(7):107224
- dc.rights © 2023 The Authors. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
- dc.subject.keyword Health sciences
- dc.subject.keyword Immune response
- dc.subject.keyword Immunology
- dc.subject.keyword Microbiology
- dc.title Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion